ClinicalTrials.Veeva

Menu
M

Midway Immunology and Research Center | Fort Pierce, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Emtricitabine
Tenofovir Alafenamide
Islatravir
Lenacapavir
Bictegravir
TAF
Doravirine
Atazanavir
ISL
Tenofovir Disoproxil Fumarate

Parent organization

This site is a part of Midway Immunology and Research Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 56 total trials

A Clinical Trial of STP0404 in Adults with HIV-1 Infection

The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living wit...

Enrolling
HIV-1-infection
Drug: High-dose STP0404 (Pirmitegravir)
Drug: Low-dose STP0404 (Pirmitegravir)

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting
HIV Infections
Drug: Lenacapavir Tablet
Drug: Zinlirvimab

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling
Human Immuno-deficiency Virus (HIV) Disease
Drug: Placebo for Budigalimab
Drug: Budigalimab

The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: DOR/ISL
Drug: ART

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: DOR/ISL

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: Placebo to DOR/ISL

The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine (DOR 100mg) and islatravir (ISL 0.75mg) will be evaluate...

Active, not recruiting
HIV-1 Infection
Drug: MK-8591A

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting
HIV-1 Infection
Drug: B/F/TAF
Drug: LEN

The goal of this clinical study is to learn how safe and effective it is to switch to an oral therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF...

Active, not recruiting
HIV-1-infection
Drug: B/F/TAF

The goals of this clinical study are to learn how Bictegravir/Emtricitabine/Tenofovir Alafenamide fixed dose combination (FDC) interacts with the bod...

Active, not recruiting
HIV-1 Infection
Drug: B/F/TAF (Adult Strength)
Drug: B/F/TAF (TOS)

The goal of this clinical study is to learn more about the experimental drugs GS-1720 (an oral, long-acting integrase strand transfer inhibitor (INST...

Enrolling
HIV-1-infection
Drug: GS-4182
Drug: Bictegravir/emtricitabine/tenofovir alafenamide

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regi...

Enrolling
HIV-1-infection
Drug: B/F/TAF
Drug: PTM ISL/LEN

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LE...

Enrolling
HIV-1-Infection
Drug: Antiretroviral Combinations
Drug: ISL/LEN

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Enrolling
HIV-1-infection
Drug: B/F/TAF
Drug: Placebo to match B/F/TAF

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting
HIV-1-infection
Drug: Optimized Background Regimen (OBR)
Drug: Oral Lenacapavir Placebo

TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere...

Active, not recruiting
HIV-1-infection
Drug: TMB-365/TMB-380

Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or a...

Enrolling
HSV Infection
Drug: Investigator's choice
Drug: Pritelivir

Trial sponsors

Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
AbbVie logo
T
Janssen (J&J Innovative Medicine) logo
A
A
Allergan logo
Bristol-Myers Squibb (BMS) logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems